Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

163.14USD
24 Apr 2017
Change (% chg)

-- (--)
Prev Close
$163.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,225,393
52-wk High
$184.20
52-wk Low
$133.64

Latest Key Developments (Source: Significant Developments)

Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine
Monday, 24 Apr 2017 04:30pm EDT 

April 24 (Reuters) - Amgen Inc ::Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine.Says co, Novartis agreed to combine capabilities to co-commercialize erenumab in U.S.; Amgen retains exclusive commercialization rights in Japan.Says Novartis gains exclusive rights to commercialize erenumab in Canada, retains existing commercialization rights in rest of the world.Says co will receive milestone payments from Novartis expected to begin in 2017; Novartis will share u.s. Commercialization costs with Amgen.Says co will book sales of erenumab in the U.S., and will pay a royalty to Novartis on net sales in the u.s..Says Novartis to book sales in rest of the world (excluding Japan), to pay co royalties on net sales in those countries; co to book sales in Japan.Says Novartis will assume agreed upon remaining global development costs up to a cap and share global development costs thereafter.  Full Article

Amgen submits applications in the U.S. and Europe to expand current indication for xgeva
Tuesday, 4 Apr 2017 09:00am EDT 

Amgen Inc : Amgen submits applications in the us and europe to expand current indication for xgeva® (denosumab) to include patients with multiple myeloma .Amgen Inc - submission of sbla to fda, application for a variation to marketing authorization to ema for xgeva.  Full Article

Amgen enters into agreement with Inovalon and Avalere
Wednesday, 29 Mar 2017 07:55am EDT 

Inovalon Holdings Inc : Amgen enters into agreement with Inovalon and Avalere to engage value-based contracting opportunities . Inovalon Holdings Inc - agreement will focus specifically on Rheumatoid Arthritis (RA) . Inovalon Holdings - Co, Avalere Health will deploy data, analytics capabilities with OBCS to support development of obcs based on value of Amgen's products .Inovalon Holdings - co, Avalere Health, an Inovalon Company, will deploy data, to support further development of OBCS based on value of Amgen's products.  Full Article

European Commission approves Amgevita for treatment of certain inflammatory diseases
Thursday, 23 Mar 2017 04:00pm EDT 

Amgen Inc : European Commission approves Amgevita™ (biosimilar adalimumab) for the treatment of certain inflammatory diseases .Amgen Inc- approval from EC grants a centralized marketing authorization with unified labeling in 28 countries that are members of EU.  Full Article

Amgen Inc reports four-year follow-up results from Repatha Osler-1 study
Tuesday, 14 Mar 2017 04:15pm EDT 

Amgen Inc : Amgen Inc - four-year follow-up results from Repatha (evolocumab) Osler-1 study . Amgen Inc - Repatha, when added to standard of care (SOC), achieved median low-density lipoprotein cholesterol (LDL-C) reductions of 57 percent at four years .Amgen - Repatha, when added to SOC achieved median LDL-C reductions with no new safety concerns identified.  Full Article

Repatha demonstrates reduced need for apheresis in patients with high LDL cholesterol
Monday, 13 Mar 2017 09:00am EDT 

Amgen Inc : Repatha (evolocumab) demonstrates reduced need for apheresis in patients with high LDL cholesterol in phase 3 study . Amgen Inc - no new safety concerns were identified in this study .Amgen - positive top-line results from a phase 3 study evaluating Repatha in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol.  Full Article

Amgen sets quarterly dividend of $1.15 per share
Tuesday, 7 Mar 2017 04:00pm EST 

Amgen Inc :Sets quarterly dividend of $1.15 per share.  Full Article

Coherus Biosciences says Amgen files trade secret action against company
Monday, 6 Mar 2017 07:00am EST 

Coherus Biosciences Inc : Coherus Biosciences Inc - Amgen has filed a trade secret action in California State Court on March 3, 2017 . Coherus Biosciences Inc - trade secret action alleges trade secret misappropriation and other claims against Coherus and other parties .Coherus Biosciences Inc - "reject theme of Amgen's complaint that Coherus has engaged, or is engaging, in a scheme to misappropriate trade secrets".  Full Article

Amgen announces positive results from planned overall survival analysis of phase 3 head-to-head ENDEAVOR trial
Tuesday, 28 Feb 2017 09:00am EST 

Amgen Inc : Announces positive results from planned overall survival analysis of phase 3 head-to-head ENDEAVOR trial . Says study met the key secondary endpoint of OS . Says phase 3 head-to-head trial showed Kyprolis significantly improved OS versus Velcade in relapsed/refractory multiple myeloma patients . Says adverse events observed in the updated analysis consistent with those previously reported for ENDEAVOR .Says plans to submit results to regulatory agencies worldwide to support potential label update to ENDEAVOR study results.  Full Article

Astrazeneca says will get $130 mln as milestone payment after Brodalumab approval
Thursday, 16 Feb 2017 07:01am EST 

Astrazeneca Plc : Partner Valeant Pharmaceuticals announced that US FDA has approved Siliq (Brodalumab) injection for treatment of adult patients with moderate-to-severe plaque psoriasis . Through a collaboration agreement, astrazeneca granted valeant exclusive license to develop and commercialise siliq globally, except in japan and certain other asian countries . Under terms of agreement, Astrazeneca will receive a milestone payment of $130 million from valeant at first regulatory approval . This milestone will be recorded in Astrazeneca financial statements as externalisation revenue .Following approval, Astrazeneca and Valeant will share profits from sale of siliq in US market..  Full Article

More From Around the Web

BRIEF-Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine

* Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine